Rigel Pharmaceuticals (NASDAQ:RIGL) has appointed Dr. Anne-Marie Duliege, as CMO, replacing Dr. Elliott Grossbard, who is retiring after 14 years with the company.
Dr. Grossbard will remain with the company, advising on the NDA filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura.
In a statement, Raul Rodriguez, president and CEO, said Dr. Duliege’s experience overseeing hematology product approvals will be put to immediate use at this crucial stage in the fostamatinib program, and she will play a significant role in the advancement of Rigel entire product pipeline.
Dr. Duliege has extensive experience in the biopharmaceutical industry, including having held leadership positions in clinical research and development at Genentech and Chiron, and most recently serving as chief of strategic development and head of immuno-oncology at ChemoCentryx.
“We are very grateful for the many contributions that Elliott has made to Rigel and our product development programs, and we continue to rely on him as we file and manage the NDA for fostamatinib in ITP,” he added.